Literature DB >> 19469676

The integrated MiniMed Paradigm REAL-Time insulin pump and glucose monitoring system: implications for improved patient outcomes.

John Mastrototaro1, Scott Lee.   

Abstract

The MiniMed Paradigm REAL-Time system (Medtronic Diabetes, Northridge, CA) was launched in 2006 and integrates real-time continuous glucose monitoring (CGM) with an insulin delivery device. The perceived advantages of such a system include the ability for patients to view and be alerted of glucose information in real-time and affords them a method to adjust insulin delivery in response to these data. Moreover, glucose, insulin, and meal information stored in the system can be uploaded by the patient to a computer using the web-based CareLink Personal Therapy Management software, or similarly by their Health Care Professional (HCP) using CareLink Pro software. The Paradigm REAL-Time system offers two distinct capabilities over conventional multiple daily injection therapy with self-monitoring of blood glucose, mainly the abilities to observe and react to glucose changes in a timely and appropriate manner using the Bolus Wizard calculator feature of the pump and to retrospectively review integrated glucose sensing and insulin delivery data. Retrospective review of uploaded data allows patients and HCPs the opportunity to modify insulin therapy and to potentially improve glycemic control without the use of a traditional glucose diary. When using CGM, the review of CareLink data can highlight interactions among meals, insulin delivery, and resulting glucose levels and supports an overall assessment of glycemic control as well as aid in the adjustment of insulin therapy regimens. Although the Paradigm REAL-Time system does not automatically adjust insulin delivery based on sensor glucose data in its current embodiment, this integrated system forms the basic platform for future generations of products in which the sensor will modify insulin dosing in semi- and ultimately fully closed-loop modalities.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19469676     DOI: 10.1089/dia.2008.0134

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN: 1520-9156            Impact factor:   6.118


  8 in total

1.  A MEMS differential viscometric sensor for affinity glucose detection in continuous glucose monitoring.

Authors:  Xian Huang; Siqi Li; Erin Davis; Charles Leduc; Yann Ravussin; Haogang Cai; Bing Song; Dachao Li; Domenico Accili; Rudolph Leibel; Qian Wang; Qiao Lin
Journal:  J Micromech Microeng       Date:  2013-05       Impact factor: 1.881

2.  A glucose sensor protein for continuous glucose monitoring.

Authors:  Jithesh V Veetil; Sha Jin; Kaiming Ye
Journal:  Biosens Bioelectron       Date:  2010-08-23       Impact factor: 10.618

3.  A hydrogel-based glucose affinity microsensor.

Authors:  Junyi Shang; Jing Yan; Zhixing Zhang; Xian Huang; Panita Maturavongsadit; Bing Song; Yuan Jia; Tieying Ma; Dachao Li; Kexin Xu; Qian Wang; Qiao Lin
Journal:  Sens Actuators B Chem       Date:  2016-03-29       Impact factor: 7.460

4.  Virtual reality and interactive gaming technology for obese and diabetic children: is military medical technology applicable?

Authors:  Thomas Brett Talbot
Journal:  J Diabetes Sci Technol       Date:  2011-03-01

5.  A Capacitive MEMS Viscometric Sensor for Affinity Detection of Glucose.

Authors:  Xian Huang; Siqi Li; Jerome Schultz; Qian Wang; Qiao Lin
Journal:  J Microelectromech Syst       Date:  2009-11-13       Impact factor: 2.417

6.  The value of real-time continuous glucose monitoring in premature infants of diabetic mothers.

Authors:  Hean-Pat Saw; Nai-Wei Yao; Cheng-Di Chiu; Jia-Yuh Chen
Journal:  PLoS One       Date:  2017-10-16       Impact factor: 3.240

Review 7.  Continuous Glucose Monitoring Systems: A Review.

Authors:  Sandeep Kumar Vashist
Journal:  Diagnostics (Basel)       Date:  2013-10-29

8.  Potential next-generation medications for self-administered platforms.

Authors:  Cheng-Han Chen; Chao-Min Cheng
Journal:  J Control Release       Date:  2021-12-24       Impact factor: 9.776

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.